Journal Mobile Options
Table of Contents
Vol. 4, No. 1, 2012
Issue release date: January – April
Section title: Published: March 2012

Open Access Gateway

Case Rep Dermatol 2012;4:47–49

Cellulitis with Leukocytopenia as an Initial Sign of Acute Promyelocytic Leukemia

Sakamoto S.a · Oiso N.a, b · Emoto M.c · Uchida S.a · Hirao A.a · Tatsumi Y.b, c · Matsumura I.c · Kawada A.a
Departments of aDermatology, bPatient Safety and Management, and cHematology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan
email Corresponding Author

Naoki Oiso

Department of DermatologyKinki University Faculty of Medicine

377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511 (Japan)

Tel. +81 72 366 0221, E-Mail

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.


Patients with hematologic malignancies are immunosuppressive and may develop cutaneous or invasive infections as a primary sign of immune suppression. Acute promyelocytic leukemia (acute myeloid leukemia M3) is caused by translocation of reciprocal chromosomal rearrangement t(15;17), which produces an oncogenic protein. We herein describe a 71-year-old man having cellulitis with leukocytopenia as a first sign of acute promyelocytic leukemia. Dermatologists and hematologists should keep in mind that patients with a hematologic malignancy, such as acute promyelocytic leukemia, can develop cellulitis with leukocytopenia.

© 2012 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Published: March 2012

Published online: 3/1/2012
Issue release date: January – April

Number of Print Pages: 3
Number of Figures: 1
Number of Tables: 0

ISSN: (Print)
eISSN: 1662-6567 (Online)

For additional information:

Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (, applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.